This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0897190008318497v1 21/5/338    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wright, B. M. Articles by Eiland, E. H. Search for Related Content Social Bookmarking                         What's this?

Current Perspectives on Extended-Spectrum Beta-Lactamase–Producing Gram-Negative Bacilli

^* To whom correspondence should be addressed. E-mail: bradley.wright{at}hhsys.org.

	Abstract

Beta-lactamase enzymes produced by gram-negative bacilli were identified before the first beta-lactam antibiotics were used to treat infections. As these enzymes adapted to available beta-lactam agents, newer beta-lactam agents were developed. Development and widespread use of the oxyimino-cephalosporins led to the emergence of extended-spectrum beta-lactamase enzymes that hydrolyze the penicillins, extended-spectrum cephalosporins, and aztreonam. There are now over 200 recognized ESBLs in a variety of gram-negative bacilli conferring resistance to penicillins, cephalosporins, a monobactam, and even carbapenems. The emergence of these enzymes is associated with poor patient outcomes, increased total health care costs, and more carbapenem use. Carbapenems should be selected judiciously to optimize outcomes while preventing further selection of extended-spectrum beta-lactamase resistance.

First published on August 8, 2008, doi:10.1177/0897190008318497

Journal of Pharmacy Practice 2008;21:338.

A more recent version of this article appeared on October 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?